Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report

verfasst von: Wade Iams, Kathyrn Eby Beckermann, Anne T. Neff, Ingrid A. Mayer, Vandana Gupta Abramson

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.
Literatur
1.
Zurück zum Zitat Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy; incidence, prevention, and management. Drug Saf. 2001;24(7):491–501.PubMedCrossRef Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy; incidence, prevention, and management. Drug Saf. 2001;24(7):491–501.PubMedCrossRef
2.
Zurück zum Zitat Symmers W. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952;2:897–903.PubMedCrossRef Symmers W. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952;2:897–903.PubMedCrossRef
3.
Zurück zum Zitat Siau K, Varughese M. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol. 2010;27:1057–9.PubMedCrossRef Siau K, Varughese M. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol. 2010;27:1057–9.PubMedCrossRef
4.
Zurück zum Zitat Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: Kaplan BS, Trompeter RS, Moake JL, editors. Hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura, (kidney disease S v. 10), vol. 22. New York: Marcel Dekker Ltd; 1992. p. 271–95. Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: Kaplan BS, Trompeter RS, Moake JL, editors. Hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura, (kidney disease S v. 10), vol. 22. New York: Marcel Dekker Ltd; 1992. p. 271–95.
5.
Zurück zum Zitat Rahdi M, Carpenter SL. Thrombotic microangiopathies. ISRN Hematol. 2012. Rahdi M, Carpenter SL. Thrombotic microangiopathies. ISRN Hematol. 2012.
7.
Zurück zum Zitat Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia. Medicine. 2012;91:195–205.PubMedCrossRef Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia. Medicine. 2012;91:195–205.PubMedCrossRef
8.
Zurück zum Zitat Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer. 1989;64(5):1017–20.PubMedCrossRef Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer. 1989;64(5):1017–20.PubMedCrossRef
9.
Zurück zum Zitat Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transpl. 1996;18(1):193–8. Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transpl. 1996;18(1):193–8.
10.
Zurück zum Zitat Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ. Drug induced thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102–11.PubMedCrossRef Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ. Drug induced thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102–11.PubMedCrossRef
11.
Zurück zum Zitat Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP. 1989;23(7-8):582–8.PubMed Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP. 1989;23(7-8):582–8.PubMed
12.
Zurück zum Zitat Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3(5):723–34.PubMed Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3(5):723–34.PubMed
13.
Zurück zum Zitat Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71(5):1882–92.PubMedCrossRef Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71(5):1882–92.PubMedCrossRef
14.
Zurück zum Zitat Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. Vasc Interv Radiol. 2009;20(2):275–6.CrossRef Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. Vasc Interv Radiol. 2009;20(2):275–6.CrossRef
Metadaten
Titel
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
verfasst von
Wade Iams
Kathyrn Eby Beckermann
Anne T. Neff
Ingrid A. Mayer
Vandana Gupta Abramson
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0568-x

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.